Capricor announces positive results from new pre-clinical study of CAP-1002
Capricor Therapeutics announced that researchers found that repeat dosing of the company’s proprietary cellular therapy yields an increase in exercise performance in a disease model of Duchenne muscular dystrophy, the mdx mouse. April 19, 2018